Silence Therapeutics (NASDAQ: SLN) Stock Analysis: Merger Offer and Price Target Insights
Key points
- Silence Therapeutics (NASDAQ: SLN) is the subject of a $20.00 per share offer from Merck KGaA, aligning with a Jefferies price target.
- The proposed acquisition values Silence Therapeutics at $1.3 billion, leading to a significant surge in its stock price.
- A legal investigation is underway to assess the fairness of the $20.00 cash offer to Silence Therapeutics shareholders.
Silence Therapeutics (NASDAQ: SLN) is a U.K. biotech developing siRNA therapies. Jefferies sets a $20.00 price target while the shares trade at $19.58. That leaves about 2.2% between the share price and the target.
The target matches Merck KGaA’s proposed $20.00 cash payment for each Silence American depositary share (ADS). An ADS is a U.S.-traded certificate representing shares in a foreign company; each Silence ADS represents three ordinary shares. The deal would add Silence’s siRNA therapies to Merck’s rare-disease pipeline.
Merck’s offer values Silence at $1.3 billion, as highlighted by The Wall Street Journal. The $20.00 offer is more than double the ADS closing price on the preceding Friday. Silence now trades at $19.58, up $10.90, or 125.58%, bringing it close to both the offer price and Jefferies’ target.
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed sale gives Silence shareholders a fair price. The narrow gap between Silence’s current price and the $20.00 cash offer makes that question relevant for holders, while the investigation itself does not establish that the price is unfair.
Read the rest, free
Pop in your email to read every article in full and search any company. It takes five seconds.
You'll get Gro's newsletter too. Leave any time in one click.
